Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
TOPOTECAN HYDROCHLORIDE (UNII: 956S425ZCY) (TOPOTECAN - UNII:7M7YKX2N15)
Fresenius Kabi USA, LLC
TOPOTECAN HYDROCHLORIDE
TOPOTECAN 4 mg in 4 mL
INTRAVENOUS
PRESCRIPTION DRUG
Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment. Topotecan hydrochloride is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. Reactions have included anaphylactoid reactions [see Adverse Reactions (6.2)] . Risk Summary Based on animal data and its mechanism of action, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. There are no ava
Topotecan hydrochloride for injection is supplied as a sterile, lyophilized, buffered, light yellow to greenish powder. Topotecan hydrochloride for injection is supplied as follows: The container closure is not made with natural rubber latex. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light; product is light-sensitive. Retain in carton. Handle and dispose of topotecan hydrochloride for injection consistent with recommendations for the handling and disposal of hazardous drugs1 .
Abbreviated New Drug Application
TOPOTECAN HYDROCHLORIDE - TOPOTECAN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION FRESENIUS KABI USA, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TOPOTECAN HYDROCHLORIDE FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TOPOTECAN HYDROCHLORIDE FOR INJECTION. TOPOTECAN HYDROCHLORIDE FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING: MYELOSUPPRESSION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ TOPOTECAN HYDROCHLORIDE CAN CAUSE SEVERE MYELOSUPPRESSION. ADMINISTER FIRST CYCLE ONLY TO PATIENTS WITH BASELINE NEUTROPHIL COUNTS GREATER THAN OR EQUAL TO 1,500/MM AND PLATELET COUNTS GREATER THAN OR EQUAL TO 100,000/MM . MONITOR BLOOD CELL COUNTS. (2.4, 5.1) RECENT MAJOR CHANGES Boxed Warning 06/2020 Contraindications (4) 06/2020 Warnings and Precautions (5.1, 5.2, 5.3) 06/2020 INDICATIONS AND USAGE Topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent. (1.1) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent. (1.2) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin. (1.3) DOSAGE AND ADMINISTRATION Ovarian cancer and small cell lung cancer: 1.5 mg/m by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle. (2.2, 2.3) Cervical cancer: 0.75 mg/m by intravenous infusion over 30 minutes on Days 1, 2, and 3 with cisplatin 50 mg/m on Day 1, of a 21-day cycle. (2.4) Renal impairment: Reduce dose if creatinine clearance (CLcr) 20 to 39 mL/min. (2.6) DOSAGE FORMS AND STRENGTHS For injection: 4 mg (free base) lyophilized powder in a single-dose vial. (3) CONTRAIND Citiți documentul complet